Tela Bio, Inc. · NASDAQ:TELA
Tela Bio — Investor Presentation (May 2026)
18 slides from Tela Bio's investor presentation, May 12, 2026
Slide 1: Investor Presentation May 2026
INVESTOR PRESENTATION May 2026
Slide 2: Forward-looking statements
This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assu med future resu
Slide 3: Our Mission
We provide innovative soft - tissue reconstruction solutions that optimize clinical outcomes by prioritizing the Preservation and Restoration of the patient’s own anatomy. 3 Our Mission
Slide 4: TELA Bio, Inc. investment highlights
TELA Bio, Inc. Advanced reinforced tissue matrix portfolio supported by compelling clinical evidence $2.6B US market opportunity 1 – still in early stages of growth Driving commercial adoption with targeted direct - sales approach Recent product launches in growing markets: robotic hernia surgery, p
Slide 5: Product Adoption Since Launch
Product Adoption Since Launch ~90,000 OviTex Reinforced Tissue Matrix (RTM) Implantations Globally 5 70+ Published or Presented Works ( OviTex + OviTex PRS) 5,000+ Hospitals Covered by GPO Access ~20,000 OviTex PRS Implantations (U.S.) 1,500 + Patients in Peer - Reviewed Publications
Slide 6: ~$1.8 Billion Annual Opportunity US Hernia Surgery Market
Complex, Moderate Ventral / Abdominal Wall Reconstruction Simple Ventral Hernia Repair Inguinal Hernia Repair Hiatal Hernia Repair ~105,000 ~395,000 ~645,000 ~42,000 $630 M $590 M $ 54 0 M $42 M 1. Sources: Millennium Research Group Reports, IMS Health Data; iData Research MedSKU . 2. Management est
Slide 7: One Comprehensive Portfolio
OviTex Core 4 - layer device No smooth sides OviTex Core is designed to reinforce primary hernia repairs where the device will not come into contact with viscera . OviTex 1S 6 - layer device 1 smooth side OviTex 1S incorporates a smooth side that is designed to minimize tissue attachment and to rein
Slide 8: 1. Hernia and Abdominal Surgeries Survey (Oct 2020). A group of 71 surgeons were
9 1. Hernia and Abdominal Surgeries Survey (Oct 2020). A group of 71 surgeons were surveyed regarding use of mesh in various he rni a repair surgeries. 2. Figures derived from Company - sponsored online poll of approximately 1,100 potential patients for hernia procedures. 3. See Medtronic plc Form 1
Slide 9: TELA Bio, the TELA Bio logo, and OviTex are each registered trademarks of TELA
TELA Bio, the TELA Bio logo, and OviTex are each registered trademarks of TELA Bio, Inc. All other trademarks and trade names ar e the property of their respective owners or holders. *Overall complications including surgical site occurrences (SSOs) and surgical site infections (SSIs) a – OviTex pati
Slide 10: TELA Bio, the TELA Bio logo, and OviTex are each registered trademarks of TELA
TELA Bio, the TELA Bio logo, and OviTex are each registered trademarks of TELA Bio, Inc. All other trademarks and trade names ar e the property of their respective owners or holders. * Kaplan - Meier survival estimate **No head - to - head clinical studies have been conducted. Due to differences in
Slide 11: Market shift towards resorbable and natural repair solutions
TELA Bio positioned to grow from a market shift towards resorbable and more “natural repair” solutions as an alternative to traditional permanent synthetics or biologics Hernia Market Evolution 2027 2021 2018 2013 Permanent Synthetic Biologic Sales Market Share <1% Robotic Procedures ( Px ) 7% Robot
Slide 12: Multiple Layers of Ovine Rumen, Three Polymer Options
14 Multiple Layers of Ovine Rumen Three Polymer Options
Slide 13: ~$800 Million Annual Opportunity US Plastic & Reconstructive Surgery Market
15 ~$800 Million Annual Opportunity US Plastic & Reconstructive Surgery Market $700M 2 1. OviTex PRS is for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcem en t in plastic and reconstructive surgery. The device is supplied sterile an
Slide 14: OviTex PRS
Specifically designed for plastic and reconstructive surgery OviTex PRS An innovative reinforced tissue matrix designed to improve outcomes by facilitating fluid management and controlling degree and direction of stretch Product Features: Layers composed of biologic building block retain biologicall
Slide 15: Leading-edge atraumatic hernia mesh fixation devices
17 Leading - edge atraumatic hernia mesh fixation devices Designed to minimize complications for patient safety and comfort
Slide 16: LIQUIFIX FIX8 & LIQUIFIX Precision
LIQUIFIX FIX8 & LIQUIFIX Precision Atraumatic liquid fixation devices Reduce the need for penetrating mechanical fixation for inguinal and femoral hernia repair Provide precise, controlled adhesive application Addresses an unmet need in the market, less damage to tissue Designed to minimize the risk
Slide 17: Quarterly Revenue and Gross Margin
19 20 +45% +39% +35% +46% +39% +11% +26% +4% +12% +26% +9% +18% +3% 60% 65% 70% 75% 80% $0 $5 $10 $15 $20 $25 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 Gross Margin Revenue ($M) Quarterly Revenue and Gross Margin Revenue Gross Margin $58.5M, +41% $69.3M, +19% $80.3M, +16%
Slide 18: Delivering Revenue Growth and Strong Margin
21 Delivering Revenue Growth and Strong Margin with Continuing Improvement Potential $19M Quarterly revenue of $19.1M, growing 3% over corresponding period of 2025 $ 39 .5M Cash and Cash Equivalents at March 31, 2026 66% Gross Margin Q1 2026 Performance